Clinical Trials Logo

Filter by:
NCT ID: NCT05198934 Active, not recruiting - Clinical trials for Colorectal Cancer (CRC)

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

CodeBreak300
Start date: April 19, 2022
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

NCT ID: NCT05198557 Recruiting - Systemic Sclerosis Clinical Trials

A Study of MT-0551 in Patients With Systemic Sclerosis

Start date: July 20, 2022
Phase: Phase 3
Study type: Interventional

The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.

NCT ID: NCT05197426 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Start date: January 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute Myeloid Leukemia (AML) and in complete remission/complete remission with incomplete blood count recovery after conventional induction chemotherapy with or without consolidation chemotherapy.

NCT ID: NCT05197049 Active, not recruiting - Crohn Disease Clinical Trials

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

GRAVITI
Start date: January 19, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT05193136 Recruiting - COPD Clinical Trials

Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

Start date: December 10, 2021
Phase:
Study type: Observational

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

NCT ID: NCT05192174 Recruiting - Solid Tumor Clinical Trials

Study of NIB101 in Participants With Advanced Solid Tumors

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

NIB101-01 study is an open-label, non-randomized Phase 1 study in participants with GM2 positive advanced solid tumor, who failed to available standard of cares to evaluate the safety and tolerability of NIB101.

NCT ID: NCT05188976 Recruiting - Respiratory Disease Clinical Trials

Assessment of End-tidal Carbon Dioxide Levels in Respiratory Disease

Start date: December 1, 2021
Phase:
Study type: Observational

The investigators aim to evaluate the correlation between PetCO2, PaCO2, and PtcCO2 in patients with respiratory diseases. The investigators also evaluate the correlation between PetCO2, PaCO2, and PtcCO2 changes over time.

NCT ID: NCT05183984 Recruiting - Ovarian Cancer Clinical Trials

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

NIRVANA-1
Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.

NCT ID: NCT05183360 Recruiting - Healthy Clinical Trials

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Start date: February 3, 2022
Phase: Phase 1
Study type: Interventional

Part I: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Japanese male subjects following oral administration of multiple rising doses. Part II: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Chinese male subjects following oral administration of single dose.

NCT ID: NCT05183347 Completed - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Start date: February 4, 2022
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses.